|Day Low/High||189.13 / 196.30|
|52 Wk Low/High||184.50 / 317.48|
U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.
It's the most random day of the week, with stocks all over the map.
Broadcom released better-than-expected 2016 fourth-quarter results, and its stock on Friday is giving a picture of where the rally could 'broaden to,' says Jim Cramer.
Lilly's sola study did not reduce amyloid plaques in the brain, adding to the likelihood that Biogen's late-stage Alzheimer's study will prove successful.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Allergan PLC has taken over the #85 spot from General Growth Properties Inc , according to ETF Channel. Below is a chart of Allergan PLC versus General Growth Properties Inc plotting their respective rank within the S&P 500 over time (AGN plotted in blue; GGP plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
Tweet on Air Force One cost overruns is ominous for companies dependent on government.
Siggi Olfasson is poised to step down as president and CEO of Teva's global generic medicines group by the end the first quarter of 2017.
Hillary isn't the only one who seems to favor workers over capital. Trump does, too.
Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'
OPEC deal is among the highlights as markets finish off an explosive November. In the portfolio, we adjust the size of some of our positions.
Stocks fluctuate on Friday afternoon in choppy trading as banks beat a retreat after days of gains.
Stocks hold mixed on Friday after U.S. jobs gains in November solidify the chances of a December rate hike.
U.S. stocks were mixed Friday, despite a better than expected jobs report.
Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer
Stock futures hold lower on Friday after U.S. job gains in November come in around forecasts.
In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.
Will investors want to wait 12 to 18 months to see Allergan's deals pay dividends?
Market should still be able to breathe once central-bank prop is removed.
Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.
Doug Kass shares his thoughts on how faster growth won't be easy and how the debt and deficits are out of control.